New Drug Cuts Seizures by Up to 91% in Children with Rare Epilepsy

For families living with Dravet syndrome, the bar for what counts as a good day has always been different from what most people can imagine. This is a condition where children can experience dozens of seizures daily, where standard antiepileptic medications barely dent the frequency, and where the developmental trajectory is profoundly affected by seizure burden from the earliest years of life. Against that backdrop, clinical trial results showing a 91% reduction in seizures from an experimental drug called zorevunersen aren't just encouraging — they represent a potential turning point for one of the most difficult-to-treat forms of epilepsy in existence.

What Is Dravet Syndrome

Dravet syndrome is a rare genetic epilepsy caused in most cases by mutations in the SCN1A gene, which encodes a sodium channel critical for regulating neuronal activity. The condition typically emerges in the first year of life, often triggered by fever, and progresses to include multiple seizure types — tonic-clonic, myoclonic, absence — that resist standard treatment. It affects roughly 1 in 15,000 to 20,000 children, meaning there are tens of thousands of affected families in the United States alone.

The developmental consequences of Dravet are significant and go beyond seizure frequency. Children with the condition frequently experience cognitive impairment, behavioral challenges, movement difficulties, and disrupted sleep. The ongoing seizure burden contributes to these outcomes but isn't entirely responsible for them — the underlying genetic disruption affects neurological development in ways that persist independent of seizure control. Any treatment that meaningfully reduces seizures also buys neurological breathing room during critical developmental windows.

How Zorevunersen Works

Zorevunersen is an antisense oligonucleotide — a type of drug that works at the RNA level rather than targeting a protein directly. Most traditional medications work by binding to proteins and altering their function. Antisense oligonucleotides work earlier in the molecular chain, binding to specific RNA sequences and modifying how genetic instructions are read and translated. In the case of Dravet syndrome, zorevunersen is designed to address the consequence of having only one functional copy of SCN1A — the haploinsufficiency that results when the mutated copy produces a defective or absent protein.

The drug targets a regulatory mechanism that normally suppresses expression of the functioning SCN1A copy, effectively releasing a natural brake and allowing the remaining good copy to produce more of the sodium channel protein. More sodium channel protein means better-regulated neuronal activity and, in principle, fewer seizures. It's a precision approach that addresses the root genetic mechanism rather than simply dampening overall neural excitability the way conventional antiepileptic drugs do. That mechanistic specificity is part of why the trial results are as striking as they are.

The Clinical Trial Results in Detail

The trial results showed seizure frequency reductions ranging up to 91% in responding patients — a number that would be extraordinary for any epilepsy treatment and is particularly remarkable for Dravet, where 50% seizure reduction is often considered a meaningful clinical response and where many patients see far less benefit from available medications. Beyond the seizure count, patients demonstrated improvements in quality of life measures that captured the broader functional picture: better caregiver assessments, improved behavior, and developmental gains that reflect what happens when seizure burden is substantially lifted.

It's worth being precise about what trial results at this stage do and don't tell us. Clinical trials for rare pediatric conditions often involve relatively small patient numbers — the rarity of the disease limits enrollment — which means the confidence intervals around efficacy estimates are wider than they'd be for a larger trial. Individual variation in response was evident: the 91% figure represents the upper end of individual responses, not the average. But even patients with more modest reductions reported meaningful quality-of-life improvements, suggesting the drug's benefit extends beyond what seizure count alone captures.

Why This Matters for the Dravet Community

The Dravet syndrome patient community has been an unusually organized and scientifically engaged advocacy group for a rare disease population. Parents of children with Dravet have driven research funding, participated in natural history studies, and pushed regulators and pharmaceutical companies to prioritize this indication for decades. The relatively recent approval of cannabidiol for Dravet and the earlier approval of stiripentol gave the community its first targeted treatment options after years of relying on general antiepileptic drugs. Zorevunersen, if it reaches approval, would be something different in kind — a treatment that addresses the genetic mechanism rather than managing symptoms.

For families, the prospect of seizure reductions of this magnitude isn't abstract. A child going from dozens of seizures a week to a small fraction of that number can attend school more consistently, can develop more normal sleep patterns, can participate in activities that were previously too dangerous, and can progress developmentally in ways that dense seizure activity prevented. These aren't marginal quality-of-life improvements — they reshape what childhood and family life look like.

The Antisense Oligonucleotide Platform

Zorevunersen's success, if confirmed through further development, adds to the growing body of evidence that antisense oligonucleotide therapies can be transformative for genetic neurological conditions. Nusinersen — the first antisense oligonucleotide approved for a neurological disease — revolutionized the treatment of spinal muscular atrophy. Tofersen has shown meaningful results in certain forms of ALS. The platform is proving its relevance across a range of conditions where the underlying genetic mechanism is defined well enough to design a targeted molecular intervention.

Most antisense oligonucleotides for neurological conditions are delivered intrathecally — injected directly into the cerebrospinal fluid — because they don't cross the blood-brain barrier efficiently when given systemically. This delivery route is more invasive than an oral medication but has become manageable as clinical experience has accumulated. Families who have navigated intrathecal injections for spinal muscular atrophy treatments have demonstrated that the delivery challenge doesn't prevent widespread clinical uptake when the drug works well enough to justify the procedure.

What Happens Next Before Potential Approval

Zorevunersen still needs to complete its regulatory journey before it becomes available to patients outside of clinical trials. The company developing the drug will need to compile the full data package from ongoing and completed trials and submit it to the FDA for review. Given the rarity and severity of Dravet syndrome, the drug is likely to qualify for breakthrough therapy designation and orphan drug status — regulatory pathways designed to expedite development and review for serious conditions with unmet medical need — which could shorten the timeline to availability.

Long-term safety data will also need to be accumulated. Antisense oligonucleotides have a generally favorable safety profile in existing approved products, but the specific effects of zorevunersen over extended treatment periods in growing children require systematic documentation. The FDA's approval decision will weigh the substantial benefit demonstrated in trials against any identified safety signals, a calculation that for a devastating pediatric condition typically favors approval when efficacy results are this compelling.

A Broader Signal for Rare Epilepsy Research

Dravet syndrome is one of dozens of rare genetic epilepsies where SCN1A and other ion channel genes are implicated. The demonstration that an antisense approach targeting the molecular consequence of SCN1A haploinsufficiency produces results this significant opens a conceptual door for the broader rare epilepsy field. Many of these conditions share the same basic challenge: a genetic disruption that existing drugs can't address at the mechanism level, leaving families with suboptimal symptom management.

As genetic sequencing becomes more accessible and the molecular causes of rare epilepsies are better characterized, the zorevunersen model — design a precise molecular intervention, target the specific genetic disruption, address root cause rather than symptoms — becomes a template worth applying systematically. The clinical results reported here are for Dravet specifically, but the research community's attention will quickly turn to what conditions might be next in line for this kind of approach.